Alere Spins Off Assets to Aid Abbott Merger

Since February 2016, we’ve followed the testy merger between Abbott (NYSE: ABT) and Alere’s (NYSE: ALR) agreement to merge, followed by the respective lawsuits, and then the price renegotiation. Half way through 2017, the $5.3 billion deal is getting closer to completion, as Alere spins off some assets to comply with antitrust regulations.

What’s Next for Managed Care?

Now that managed care giants are blocked from acquiring each other, they may look outside the sector for growth.

Abbott to Alere: It’s You, Not Me

The party’s about over for the $5.8 billion Abbott (NYSE: ABT) acquisition of Alere Inc. (NYSE: ALR). Everything was bright and rosy when Abbott agreed to pay $56.00 per share for the point-of-care diagnostics and services company. Now, the $177 million termination fee Abbott faces to get out of the deal looks pretty cheap. In April, Abbott reportedly […]

Abbott’s $30.7B Deal Boosts Medical Device M&A

Medical device deals are back in fashion. In the first four months of 2016, 41 deals were announced in this sector, compared with just 30 for the comparable time period in 2015. Spending on deals in this sector has already hit $42.7 billion, compared with $5.7 billion in the first four months of 2015. The largest by far this […]

Point-of-Care Diagnostics Company Commands $5.8 Billion

Abbott Laboratories (NYSE: ABT) may be known for its branded generic pharmaceuticals, but it just boosted its diagnostics division with the $5.8 billion acquisition of Alere Inc. (NYSE: ALR). Alere provides point-of care diagnostics and services for the infectious disease, cardiometabolic disease, and toxicology in the United States and worldwide. Abbott will pay $56 per common share, […]